Tumor microenvironment-responsive BSA nanocarriers for combined chemo/chemodynamic cancer therapy

Journal of Nanobiotechnology

Ruiyi Zhang¹  Zhiyuan Ma¹  Yugui Tao¹  Weiwei Zhang¹  Wanzhen Li¹  Kai Yang²  Pei Pei²  Teng Liu² 

[1] School of Biological and Food Engineering, Anhui Polytechnic University;State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University;

关键词: Tumor microenvironment;    Chemodynamic therapy;    Chemotherapy;    Bovine serum albumin;    Nanoscale coordination polymers;   

DOI  :  10.1186/s12951-022-01442-5

来源: DOAJ

【 摘 要 】

Abstract Tumor microenvironment (TME), characterized by high glutathione (GSH), high hydrogen peroxide (H2O2) and acidic pH levels, is favorable for the growth, invasion and metastasis of cancer cells. Taking advantage of the specific characteristics of tumors, TME-responsive GCBD NPs are designed to deliver nanoscale coordination polymers (NCPs, GA-Cu) and chemotherapy drugs (doxorubicin, DOX) based on bovine serum albumin (BSA) nanocarriers into cancer cells for combined chemodynamic therapy (CDT) and chemotherapy. In an acidic environment, GCBD NPs could release approximately 90% copper ions, which can not only consume overexpressed GSH to modulate the TME but can also react with endogenous H2O2 in a Fenton-like reaction to achieve the CDT effect. Meanwhile, the released DOX could enter the nucleus of tumor cells and affect their proliferation to achieve efficient chemotherapy. Both in vitro and in vivo experiments showed that GCBD NPs had good biosafety and could effectively inhibit the growth of cancer cells. GCBD NPs are promising as a biocompatible nanoplatform to exploit TME characteristics for combined chemo and chemodynamic therapy, providing a novel strategy to eradicate tumors with high efficiency and specificity. Graphical Abstract

【 授权许可】

Unknown